Maple Peak Investments Inc (MAP) Fair Value & Analysis
Healthcare · CA · Market cap A$38.4M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.2400 to A$0.0277 (−88.5%) since Jun 24, 2026. Share price −42.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0361 – A$0.1024 · fair‑value band A$0.0277 – A$0.0316 · the A$0.0390 price screens above the A$0.0277 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Maple Peak Investments Inc (MAP) currently trades at A$0.0390, while our model-based Fair Value estimate is A$0.0277 — implying the stock looks roughly 29.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$14.9M. Revenue declined 9.5% year over year. It earns a return on equity of -60.0%. The balance sheet holds a net cash position of A$8.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Maple Peak Investments Inc. does not have significant operations. The company focuses on investing in casinos, gaming and game of chance, leisure and entertainment, and resort companies. Maple Peak Investments Inc. was incorporated in 2013 and is headquartered in Richmond, Canada.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Maple Peak Investments Inc reported revenue of A$15.7M in FY2024 versus A$3.7M in FY2020, a compound +43.1%/yr. Reported net income was −A$14.9M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Maple Peak Investments Inc (MAP) undervalued?
What is the fair value of MAP?
What is the quality score of MAP?
What is the revenue of Maple Peak Investments Inc (MAP)?
What is the net profit margin of MAP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.